Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite's food vacuole and alter drug sensitivities

Serena Pulcini, Henry M. Staines, Andrew H. Lee, Sarah H. Shafik, Guillaume Bouyer, Catherine M. Moore, Daniel A. Daley, Matthew J Hoke, Lindsey M. Altenhofen, Heather J. Painter, Jianbing Mu, David J. P. Ferguson, Manuel Llinas, Rowen E. Martin, David A. Fidock, Roland Cooper, Sanjeev Krishna, Jainbing Mu

Research output: Contribution to journalArticlepeer-review

Abstract

Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, are the major determinant of chloroquine resistance in this lethal human malaria parasite. Here, we describe P. falciparum lines subjected to selection by amantadine or blasticidin that carry PfCRT mutations (C101F or L272F), causing the development of enlarged food vacuoles. These parasites also have increased sensitivity to chloroquine and some other quinoline antimalarials, but exhibit no or minimal change in sensitivity to artemisinins, when compared with parental strains. A transgenic parasite line expressing the L272F variant of PfCRT confirmed this increased chloroquine sensitivity and enlarged food vacuole phenotype. Furthermore, the introduction of the C101F or L272F mutation into a chloroquine-resistant variant of PfCRT reduced the ability of this protein to transport chloroquine by approximately 93 and 82%, respectively, when expressed in Xenopus oocytes. These data provide, at least in part, a mechanistic explanation for the increased sensitivity of the mutant parasite lines to chloroquine. Taken together, these findings provide new insights into PfCRT function and PfCRT-mediated drug resistance, as well as the food vacuole, which is an important target of many antimalarial drugs.

Original languageAmerican English
Article number14552
Pages (from-to)14552
JournalScientific Reports
Volume5
StatePublished - Sep 30 2015

Funding

This work was supported by the European Community’s Seventh Framework Programme, FP7/2007-2013 (Marie Curie-funded Initial Training Network InterMal, 215281-2 to SK and NanoMal, 304948 to SK and HMS), the NIH (R01 AI50234 to DAF and R01 AI071121 to RAC), the Australian National Health and Medical Research Council (Grant 1007035 and Fellowship 1053082 to REM) and the Burroughs Wellcome Fund - Investigators in Pathogenesis of Infectious Disease award (1007041.02 to ML).

FundersFunder number
Australian National Health and Medical Research Council1053082, 1007035
FP7/2007304948, 215281-2
National Institutes of HealthR01 AI50234
National Institute of Allergy and Infectious DiseasesR01AI071121
Burroughs Wellcome Fund1007041.02
Seventh Framework Programme

    Keywords

    • Antiparasitic agents
    • DNA sequencing
    • Microscopy
    • Parasite Biology
    • Transmembrane protein PfCRT
    • Xenopus laevis oocytes
    • Malaria parasites
    • Artemisinin
    • Antimalarial
    • Polymorphisms
    • Mechanism
    • Metaanalysis
    • Piperaquine
    • Expression

    Disciplines

    • Life Sciences
    • Medicinal Chemistry and Pharmaceutics
    • Parasitic Diseases
    • Pharmacology, Toxicology and Environmental Health
    • Biology
    • Immunology and Infectious Disease
    • Physiology

    Cite this